SPOTLIGHT: ZymoGenetics inks $198M deal


ZymoGenetics is pocketing a $30 million upfront payment from Bayer HealthCare for a global license to help sell the blood clotting drug rThrombin. An FDA approval would trigger another $40 million payday in a licensing deal valued at up to $198 million plus royalties. Report